Reading time is 4 mins
.
.
SCIENTIFIC WORLD ARGUES: IS MUTATED VIRUS MORE EFFECTIVE ON YOUNG PEOPLE?
- The corona virus has been considered to be more effective on older people to date. Why are scientists now starting to think that the variant seen in Turkey is more effective on young people?
. - Britain is trying to combat the mutating corona virus. Health Minister has announced that the new variant is being transmitted faster, while scientists continue to investigate the effects of the mutated virus.
.
- The mutated virus has been on island for two months. According to observations made by British scientists, the increase in the number of cases could not be prevented even if vaccination studies had begun. In addition, there was a decrease in the age of Covid patients treated in hospitals. This statistic has led to panic that the virus is also starting to pose a danger to younger citizens.
.
- With the average age of patients falling, the virus may also have become more deadly, according to data obtained in the UK. British scientists said that the virus also causes severe disease in young citizens who can survive the disease with mild symptoms.
.
WE THINK THE VIRUS IS AGGRAVATING THE DISEASE
- Dr from University Of Exeter “So we think it makes citizens sicker and more contagious,” said, noting that they found that the virus, along with the mutation, gets into cells more easily.” he said.
.
- Virologists say that because of the mutation in the new variant’s spike protein, the virus gets into cells more easily and infects people more easily. Dr. and some doctors therefore attribute the increase in the number of young and female patients being treated in hospitals to the mutation that occurs in the virus’s spike protein.
.
A DECREASE IN THE AVERAGE AGE OF PATIENTS WAS RECORDED
- The mutation virus was first detected in the UK in September 2020. September to November the average age of patients treated in intensive care was 61.4, according to statistics. December 1 to January 21, however, this figure fell to 58.9. The proportion of female patients admitted to intensive care increased from 30.1 per cent to 35.1 per cent based on the same periods. Before national shutdown was announced on January 4, December also saw an increase in the rate of admission of citizens aged 18-54 in hospitals.
.
ACCORDING TO SOME DOCTORS, THIS IS NOT THE ONLY REASON FOR THE NEW VARIANT
- British scientists note that in addition to the new variant, during the holiday period, citizens come into much more contact with each other, and there is a negative change in the way young people behave. Dr from Oxford points out that the age of the patients he treated in the process is younger, and this rate is closer to the rate at the beginning of the epidemic. He stresses that the new variant increases the rate of transmission, as well as the effect of increased socialization over the festive period.
.
COULD THE NEW VARIANT BE MORE DEADLY?
- Research is ongoing into whether the new variant could be more deadly. The variant identified in the UK has now become dominant in society. In the country, the new variant is estimated to be 30 percent to 70 percent more contagious than before. The government health advisory panel also highlighted the possibility that the variant could be 30 per cent to 40 per cent more deadly.
.
- A consensus among scientists on this issue has not yet been reached. Professor at University of Leicester stressed that socialization is allowed too much during the winter months, which leads to an increase in hospitalization rates. “Viruses in general mutate in a way that is more contagious and less deadly, ” was said, noting that there is not enough evidence as to whether the new variant will be more deadly.” said.
.
DISEASE RATE AND INFLAMMATION MAY INCREASE IF CELL BINDING IS INCREASED
- There is no serious difference yet in the rate of disease caused by the new variant compared to the first virus. But it is suspected that because the virus can move more easily in the patient, it can overcome the body’s immune response.
.
- Chairman of the Advisory Group on new and emerging respiratory virus threats, Dr. said: “if the virus has become more strongly attached to cells, it may be enough to grab a lower dose of the virus to become infected. This, in turn, will increase the risk of transmission of the virus. If the virus can move faster in cells in the lungs, it can increase the rate of disease and inflammation. In this case, the virus can progress faster than the body can react.” was said.
.
THE PROBABILITY OF DEATH WAS FOUND TO BE 30 PER CENT HIGHER
- British researchers matched infected people by dividing them into data such as age, gender and ethnicity in order for pressure on the health system to reduce death rates. The author of one of the studies by the London School of Hygiene & Tropical Medicine, found that if two people from the same group were infected, the patient with the new variant was 30 percent more likely to die. Again, a group of researchers from Imperial Collage London, Dr. He obtained a similar result to the data obtained by his group.
.
.
.
President of Organ Transplant Center at MedicalPark Hospital Antalya
Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.
Physician's Resume:
Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.
Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.
In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.
Awards:
Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.
Certificates:
Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .
Professional Members:
American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.
Disclaimer:
Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.
Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.
Physician's Resume:
Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.
Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.
In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.
Awards:
Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.
Certificates:
Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .
Professional Members:
American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.
Disclaimer:
Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.
Latest posts by Medically Reviewed by Professor Doctor Alper Demirbaş (see all)